What are the side effects of intravenous immunoglobulin (IVIG) therapy for Guillain‑Barré syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

IVIG Therapy Side Effects in Guillain-Barré Syndrome

IVIG therapy for GBS is generally safe but carries important risks including hypersensitivity reactions, renal dysfunction, thrombosis, aseptic meningitis, and various minor adverse effects that occur in approximately 40% of patients.

Serious Life-Threatening Complications

Hypersensitivity and Anaphylaxis

  • Severe hypersensitivity reactions and anaphylaxis can occur even in patients who previously tolerated IVIG 1
  • Patients with IgA deficiency and anti-IgA antibodies are at highest risk and IVIG is contraindicated in this population 1
  • If hypersensitivity develops, immediately discontinue infusion and institute appropriate treatment 1

Renal Dysfunction and Failure

  • Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death have been reported 1
  • High-risk patients include those with pre-existing renal insufficiency, diabetes, age >65, volume depletion, sepsis, paraproteinemia, or concurrent nephrotoxic drugs 1
  • Ensure patients are adequately hydrated before administration 1
  • Monitor BUN and creatinine before infusion and at appropriate intervals; discontinue if renal function deteriorates 1
  • A 2026 case report documented AKI from osmotic nephrosis with maltose-based IVIG requiring ICU care and hemofiltration 2

Thrombotic Events

  • Thrombosis may occur following IVIG treatment, including in patients without known risk factors 1
  • Risk factors include advanced age, prolonged immobilization, hypercoagulable conditions, history of thrombosis, estrogen use, indwelling catheters, hyperviscosity, and cardiovascular risk factors 1
  • Deep vein thrombosis occurred in 2 patients in a prospective study of 117 patients 3
  • Recent 2025 data shows thromboembolic events occurred more frequently with second IVIG courses 4
  • Administer at minimum dose and infusion rate in high-risk patients; ensure adequate hydration 1

Neurological Complications

  • Aseptic meningitis syndrome (AMS) typically begins within several hours to 2 days after IVIG; discontinuation results in remission within several days 1
  • Acute encephalopathy is rare but documented, presenting with decreased consciousness, agitation, and brain edema; one case required plasma exchange for resolution 5

Cardiovascular Complications

  • Myocarditis is a rare complication that may result from the inflammatory/autoimmune response in GBS itself or as an IVIG adverse effect 2
  • One case presented with elevated troponin, reduced ejection fraction, and ECG changes requiring ICU care 2

Common Minor Adverse Effects

Frequency and Spectrum

  • Adverse events occur in approximately 42.7% of patients, with most being minor 3
  • The majority present as asymptomatic laboratory changes 3

Specific Minor Reactions

  • Headache occurs in approximately 7-17% of patients 3, 6
  • Pre-infusion with methylprednisolone does NOT prevent headache 6
  • Rash or mild headache occurred in 8 patients, especially when infusion flow exceeded 10 g/h 3

Dermatologic Reactions

  • Dyshidrotic eczema (pompholyx) is an uncommon but recognized cutaneous reaction 7, 8
  • Presents as pruritic vesicles on palms, fingers, and soles 7, 8
  • Typically develops 4 days from start to 5 days after completion of therapy 7
  • Can become widespread and generalized, persisting for 4 weeks 7
  • Responds to topical steroids with complete resolution in 2 weeks 8
  • May recur with subsequent IVIG courses 8

Laboratory Abnormalities

  • Transient liver function disturbances occurred in 2/9 patients receiving IVIG alone and 6/9 patients receiving combined methylprednisolone and IVIG 6

Metabolic Disturbances

  • Hyperproteinemia, increased serum viscosity, and hyponatremia may occur 1
  • Critical distinction: Differentiate true hyponatremia from pseudohyponatremia related to hyperproteinemia, as treating pseudohyponatremia with free water restriction can cause volume depletion, increased viscosity, and higher thrombosis risk 1

Risk Mitigation Strategies

Pre-Treatment Assessment

  • Screen for IgA deficiency with anti-IgA antibodies in patients with hypersensitivity history 1
  • Assess baseline renal function (BUN, creatinine) 1
  • Consider baseline blood viscosity assessment in patients with cryoglobulins, high triglycerides, or monoclonal gammopathies 1
  • Ensure adequate hydration status 1

Infusion Protocol

  • Start at 0.01 mL/kg/min (0.5 mg/kg/min) 1
  • If tolerated for 30 minutes, gradually increase to maximum 0.10 mL/kg/min (5 mg/kg/min) 1
  • Keep infusion flow ≤10 g/h to minimize headache and rash 3
  • Monitor vital signs throughout infusion 1
  • Slow or stop if adverse reactions occur; may resume at lower rate if symptoms subside 1

High-Risk Populations

  • Patients with pre-existing heart or renal insufficiency or immobilized patients are at higher risk for complications 3
  • Use minimum dose and slowest infusion rate practicable in these patients 1

Important Caveat Regarding Second IVIG Course

A second course of IVIG in treatment-unresponsive GBS does NOT improve clinical outcomes and significantly increases serious adverse events, particularly thromboembolic complications 4, 9. The 2025 SID-GBS trial demonstrated that while a second dose increases serum IgG levels as predicted, it provides no clinical benefit and carries higher risk 4. Current evidence with low certainty suggests no beneficial effect of further IVIG in unresponsive GBS 9.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.